Literature DB >> 26555393

Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection.

Joseph G Skeate1,2, Tania B Porras1, Andrew W Woodham1, Julie K Jang3, Julia R Taylor1, Heike E Brand2, Thomas J Kelly1,2, Jae U Jung1,2, Diane M Da Silva4,2, Weiming Yuan1,2, W Martin Kast1,2,4.   

Abstract

Herpes simplex virus (HSV) was originally implicated in the aetiology of cervical cancer, and although high-risk human papillomavirus (HPV) is now the accepted causative agent, the epidemiological link between HSV and HPV-associated cancers persists. The annexin A2 heterotetramer (A2t) has been shown to mediate infectious HPV type 16 (HPV16) uptake by human keratinocytes, and secretory leukocyte protease inhibitor (SLPI), an endogenous A2t ligand, inhibits HPV16 uptake and infection. Interestingly, HSV infection induces a sustained downregulation of SLPI in epithelial cells, which we hypothesized promotes HPV16 infection through A2t. Here, we show that in vitro infection of human keratinocytes with HSV-1 or HSV-2, but not with an HSV-1 ICP4 deletion mutant that does not downregulate SLPI, leads to a >70% reduction of SLPI mRNA and a >60% decrease in secreted SLPI protein. Consequently, we observed a significant increase in the uptake of HPV16 virus-like particles and gene transduction by HPV16 pseudovirions (two- and 2.5-fold, respectively) in HSV-1- and HSV-2-infected human keratinocyte cell cultures compared with uninfected cells, whereas exogenously added SLPI reversed this effect. Using a SiMPull (single-molecule pulldown) assay, we demonstrated that endogenously secreted SLPI interacts with A2t on epithelial cells in an autocrine/paracrine manner. These results suggested that ongoing HSV infection and resultant downregulation of local levels of SLPI may impart a greater susceptibility for keratinocytes to HPV16 infection through the host cell receptor A2t, providing a mechanism that may, in part, provide an explanation for the aetiological link between HSV and HPV-associated cancers.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26555393      PMCID: PMC4804641          DOI: 10.1099/jgv.0.000341

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  41 in total

Review 1.  Herpes simplex virus: receptors and ligands for cell entry.

Authors:  Patricia G Spear
Journal:  Cell Microbiol       Date:  2004-05       Impact factor: 3.715

2.  Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer.

Authors:  Jennifer S Smith; Rolando Herrero; Cristina Bosetti; Nubia Muñoz; F Xavier Bosch; José Eluf-Neto; Xavier Castellsagué; Chris J L M Meijer; Adriaan J C Van den Brule; Silvia Franceschi; Rhoda Ashley
Journal:  J Natl Cancer Inst       Date:  2002-11-06       Impact factor: 13.506

Review 3.  The evolving field of human papillomavirus receptor research: a review of binding and entry.

Authors:  Adam B Raff; Andrew W Woodham; Laura M Raff; Joseph G Skeate; Lisa Yan; Diane M Da Silva; Mario Schelhaas; W Martin Kast
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

4.  Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm.

Authors:  Y Kawana; K Kawana; H Yoshikawa; Y Taketani; K Yoshiike; T Kanda
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Serologic evidence of herpes simplex virus 1 infection and oropharyngeal cancer risk.

Authors:  J R Starr; J R Daling; E D Fitzgibbons; M M Madeleine; R Ashley; D A Galloway; S M Schwartz
Journal:  Cancer Res       Date:  2001-12-01       Impact factor: 12.701

6.  Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression.

Authors:  Andrew W Woodham; Adam B Raff; Laura M Raff; Diane M Da Silva; Lisa Yan; Joseph G Skeate; Michael K Wong; Yvonne G Lin; W Martin Kast
Journal:  J Immunol       Date:  2014-04-09       Impact factor: 5.422

7.  Small molecule inhibitors of the annexin A2 heterotetramer prevent human papillomavirus type 16 infection.

Authors:  Andrew W Woodham; Julia R Taylor; Andrew I Jimenez; Joseph G Skeate; Thomas Schmidt; Heike E Brand; Diane M Da Silva; W Martin Kast
Journal:  J Antimicrob Chemother       Date:  2015-02-23       Impact factor: 5.790

8.  Annexin A2 and S100A10 regulate human papillomavirus type 16 entry and intracellular trafficking in human keratinocytes.

Authors:  Agnieszka Dziduszko; Michelle A Ozbun
Journal:  J Virol       Date:  2013-05-01       Impact factor: 5.103

9.  Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses.

Authors:  Saeed Shafti-Keramat; Alessandra Handisurya; Ernst Kriehuber; Guerrino Meneguzzi; Katharina Slupetzky; Reinhard Kirnbauer
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States.

Authors:  Shannon Stokley; Jenny Jeyarajah; David Yankey; Maria Cano; Julianne Gee; Jill Roark; Robinette C Curtis; Lauri Markowitz
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-07-25       Impact factor: 17.586

View more
  6 in total

1.  Distribution and factors associated with salivary secretory leukocyte protease inhibitor concentrations.

Authors:  S Rahman; C M Pierce Campbell; B N Torres; M T O'Keefe; D J Ingles; L L Villa; R J Carvalho da Silva; R C Cintra; E Lazcano-Ponce; J Salmeron; M Quiterio; A R Giuliano
Journal:  Oral Dis       Date:  2016-08-17       Impact factor: 3.511

2.  Secretory Leukocyte Protease Inhibitor Expression and High-Risk HPV Infection in Anal Lesions of HIV-Positive Patients.

Authors:  Alcina F Nicol; Laurie L Brunette; Gerard J Nuovo; Beatriz Grinsztejn; Ruth K Friedman; Valdiléa G Veloso; Cynthia B Cunha; José R Coutinho; Cecilia Vianna-Andrade; Nathalia S Oliveira; Andrew W Woodham; Diane M DA Silva; W Martin Kast
Journal:  J Acquir Immune Defic Syndr       Date:  2016-09-01       Impact factor: 3.731

3.  Unusual and unique distribution of anal high-risk human papillomavirus (HR-HPV) among men who have sex with men living in the Central African Republic.

Authors:  Ralph-Sydney Mboumba Bouassa; Marcel Mbeko Simaleko; Serge Police Camengo; Christian Diamant Mossoro-Kpinde; David Veyer; Mathieu Matta; Leman Robin; Jean De Dieu Longo; Gérard Grésenguet; Hélène Péré; Jean-François Meye; Laurent Belec
Journal:  PLoS One       Date:  2018-05-24       Impact factor: 3.240

4.  Syndemic synergy of HPV and other sexually transmitted pathogens in the development of high-grade anal squamous intraepithelial lesions.

Authors:  Jenny C McCloskey; W Martin Kast; James P Flexman; Dugald McCallum; Martyn A French; Michael Phillips
Journal:  Papillomavirus Res       Date:  2017-11-07

5.  Transcriptomic Analysis of Human Keratinocytes Treated with Galactomyces Ferment Filtrate, a Beneficial Cosmetic Ingredient.

Authors:  Akiko Nakajima; Nahoko Sakae; Xianghong Yan; Tomohiro Hakozaki; Wenzhu Zhao; Timothy Laughlin; Masutaka Furue
Journal:  J Clin Med       Date:  2022-08-09       Impact factor: 4.964

6.  Theta-Defensins Inhibit High-Risk Human Papillomavirus Infection Through Charge-Driven Capsid Clustering.

Authors:  Joseph G Skeate; Wouter H Segerink; Mauricio D Garcia; Daniel J Fernandez; Ruben Prins; Kim P Lühen; Féline O Voss; Diane M Da Silva; W Martin Kast
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.